Lv3
250 积分 2024-03-04 加入
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
4小时前
待确认
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
20天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
20天前
已完结
Becotatug Vedotin: First Approval
1个月前
已完结
Zhou Q, Yu Y, Xing L, et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. Med. 2025;6(1):100513. doi:10.1016/j.medj.2024.09.002
1个月前
已完结
Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer
2个月前
已关闭
Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey
2个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
3个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
3个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
